ArticleIBRO neuroscience reports2025

Assessment of differences in clinical consequences between rituximab and interferon recipients in multiple sclerosis patients after recovery from COVID-19.

Arash Musa Al-Rezai Aghdam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.